98 related articles for article (PubMed ID: 6220269)
41. A comparison of danazol and placebo in the treatment of adult idiopathic gynaecomastia: results of a prospective study in 55 patients.
Jones DJ; Holt SD; Surtees P; Davison DJ; Coptcoat MJ
Ann R Coll Surg Engl; 1990 Sep; 72(5):296-8. PubMed ID: 2221763
[TBL] [Abstract][Full Text] [Related]
42. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency.
Ly LP; Jimenez M; Zhuang TN; Celermajer DS; Conway AJ; Handelsman DJ
J Clin Endocrinol Metab; 2001 Sep; 86(9):4078-88. PubMed ID: 11549629
[TBL] [Abstract][Full Text] [Related]
43. Elevated serum IGF-I, but unaltered sex steroid levels, in healthy boys with pubertal gynaecomastia.
Mieritz MG; Sorensen K; Aksglaede L; Mouritsen A; Hagen CP; Hilsted L; Andersson AM; Juul A
Clin Endocrinol (Oxf); 2014 May; 80(5):691-8. PubMed ID: 24033660
[TBL] [Abstract][Full Text] [Related]
44. Biochemical features of eugonadal patients with idiopathic gynaecomastia: A retrospective cross-sectional study.
Vita R; Capodicasa G; Di Bari F; Amadeo G; Stagno D'Alcontres F; Benvenga S
Andrologia; 2021 Mar; 53(2):e13962. PubMed ID: 33411368
[TBL] [Abstract][Full Text] [Related]
45. Treatment of gynecomastia with prednisone: case report and literature review.
Jin Y; Fan M
J Int Med Res; 2019 May; 47(5):2288-2295. PubMed ID: 30958070
[TBL] [Abstract][Full Text] [Related]
46. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study.
Kunelius P; Lukkarinen O; Hannuksela ML; Itkonen O; Tapanainen JS
J Clin Endocrinol Metab; 2002 Apr; 87(4):1467-72. PubMed ID: 11932266
[TBL] [Abstract][Full Text] [Related]
47. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
[TBL] [Abstract][Full Text] [Related]
48. Comparison of plasma androgen glucuronide levels after percutaneous or peroral androgen treatment in men: evidence for important splanchnic contribution to plasma 17 beta-hydroxyandrogen glucuronides.
Giagulli VA; Verdonck L; Deslypere JP; Giorgino R; Vermeulen A
J Clin Endocrinol Metab; 1993 Feb; 76(2):429-31. PubMed ID: 8432786
[TBL] [Abstract][Full Text] [Related]
49. Management of physiological gynaecomastia with tamoxifen.
Khan HN; Rampaul R; Blamey RW
Breast; 2004 Feb; 13(1):61-5. PubMed ID: 14759718
[TBL] [Abstract][Full Text] [Related]
50. Interaction of delta-5-androstene-3beta, 17beta-diol with estradiol and dihydrotestosterone receptors in human myometrial and mammary cancer tissue.
Poortman J; Prenen JA; Schwarz F; Thijssen JH
J Clin Endocrinol Metab; 1975 Mar; 40(3):373-9. PubMed ID: 163841
[TBL] [Abstract][Full Text] [Related]
51. Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment.
Mira JA; Lozano F; Santos J; Ramayo E; Terrón A; Palacios R; León EM; Márquez M; Macías J; Fernández-Palacin A; Gómez-Mateos J; Pineda JA;
Antivir Ther; 2004 Aug; 9(4):511-7. PubMed ID: 15456082
[TBL] [Abstract][Full Text] [Related]
52. Estradiol and high-dose dihydrotestosterone treatment causes changes in cynomolgus monkey prostate volume and histology identical to those caused by testosterone alone.
Kamischke A; Weinbauer GF; Semjonow A; Lerchl A; Richter KD; Nieschlag E
J Androl; 1999; 20(5):601-10. PubMed ID: 10520572
[TBL] [Abstract][Full Text] [Related]
53. [45,X/46,XY/47,XXY chromosome mosaicism as a cause of hypergonadotropic hypogonadism diagnosed in late middle age].
Kreft B; Greiwe M; Schwinger E; Peters A
Dtsch Med Wochenschr; 1995 Aug; 120(33):1114-7. PubMed ID: 7656835
[TBL] [Abstract][Full Text] [Related]
54. Dihydrotestosterone treatment in men with coronary artery disease. I. Influence on sex hormones, lipid profile, insulin resistance and fibrinogen.
Barud W; Palusiński R; Makaruk B; Hanzlik J
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):241-6. PubMed ID: 15323199
[TBL] [Abstract][Full Text] [Related]
55. Childhood gynecomastia: a clinical analysis of 240 cases.
Li RZ; Xia Z; Lin HH; Wen Y; Wu J; Wang HW
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Oct; 9(5):404-6. PubMed ID: 17937844
[TBL] [Abstract][Full Text] [Related]
56. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial.
Plourde PV; Reiter EO; Jou HC; Desrochers PE; Rubin SD; Bercu BB; Diamond FB; Backeljauw PF
J Clin Endocrinol Metab; 2004 Sep; 89(9):4428-33. PubMed ID: 15356042
[TBL] [Abstract][Full Text] [Related]
57. Male partial hypogonadotrophic hypogonadism with gynaecomastia and metabolic syndrome.
Ahsan T; Banu Z
J Coll Physicians Surg Pak; 2012 Feb; 22(2):105-7. PubMed ID: 22313648
[TBL] [Abstract][Full Text] [Related]
58. Transdermal testosterone therapy in the treatment of male hypogonadism.
Ahmed SR; Boucher AE; Manni A; Santen RJ; Bartholomew M; Demers LM
J Clin Endocrinol Metab; 1988 Mar; 66(3):546-51. PubMed ID: 3350906
[TBL] [Abstract][Full Text] [Related]
59. Decline of plasma 5alpha-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levels.
Gooren LJ; Saad F; Haide A; Yassin A
Andrologia; 2008 Oct; 40(5):298-302. PubMed ID: 18811920
[TBL] [Abstract][Full Text] [Related]
60. Compounded percutaneous testosterone gel: use and effects in hypogonadal men.
Cutter CB
J Am Board Fam Pract; 2001; 14(1):22-32. PubMed ID: 11206690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
